The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type
- PMID: 28264468
- PMCID: PMC6155368
- DOI: 10.3390/molecules22030368
The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type
Abstract
This is an analysis from a chemical point of view of the 22 drugs accepted by the FDA during 2016. The different drugs from the 2016 "harvest" have been classified according to their chemical structure: antibodies; TIDES (oligonucleotides and peptides); amino acids and natural products; drug combination; and small molecules.
Keywords: API; biologics; chemical entities; drug discovery; peptide; small molecules.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules.Molecules. 2018 Feb 27;23(3):533. doi: 10.3390/molecules23030533. Molecules. 2018. PMID: 29495494 Free PMC article. Review.
-
The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules.Molecules. 2019 Feb 23;24(4):809. doi: 10.3390/molecules24040809. Molecules. 2019. PMID: 30813407 Free PMC article. Review.
-
The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules.Molecules. 2023 Jan 20;28(3):1038. doi: 10.3390/molecules28031038. Molecules. 2023. PMID: 36770706 Free PMC article. Review.
-
The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules.Molecules. 2024 Jan 25;29(3):585. doi: 10.3390/molecules29030585. Molecules. 2024. PMID: 38338330 Free PMC article. Review.
-
The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.Molecules. 2020 Feb 9;25(3):745. doi: 10.3390/molecules25030745. Molecules. 2020. PMID: 32050446 Free PMC article. Review.
Cited by
-
2019 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel). 2020 Mar 5;13(3):40. doi: 10.3390/ph13030040. Pharmaceuticals (Basel). 2020. PMID: 32151051 Free PMC article. Review.
-
Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021.Biomedicines. 2022 Sep 19;10(9):2325. doi: 10.3390/biomedicines10092325. Biomedicines. 2022. PMID: 36140426 Free PMC article. Review.
-
Increased MSX level improves biological productivity and production stability in multiple recombinant GS CHO cell lines.Eng Life Sci. 2020 Jan 9;20(3-4):112-125. doi: 10.1002/elsc.201900124. eCollection 2020 Mar. Eng Life Sci. 2020. PMID: 32874175 Free PMC article.
-
Optogenerapy: When bio-electronic implant enters the modern syringe era.Porto Biomed J. 2017 Sep-Oct;2(5):145-149. doi: 10.1016/j.pbj.2017.07.001. Epub 2017 Jul 29. Porto Biomed J. 2017. PMID: 32258609 Free PMC article.
-
The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules.Molecules. 2018 Feb 27;23(3):533. doi: 10.3390/molecules23030533. Molecules. 2018. PMID: 29495494 Free PMC article. Review.
References
-
- Joint Research Centre European Commission . The 2016 EU Industrial R&D Investment Scoreboard. Publications Office of the EU; London, UK: 2016.
-
- U.S. Food and Drug Administration (FDA) [(accessed on 5 February 2017)]; Available online: http://www.accessdata.fda.gov/scripts/cder/daf/
-
- Jarvis L.M. The Year in New Drugs. Chemical & Engineering News; Washington, DC, USA: 2017. pp. 28–32.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical